Status:
COMPLETED
Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured
Lead Sponsor:
Rennes University Hospital
Conditions:
Unfractionated Heparin Treatment
Eligibility:
All Genders
18+ years
Brief Summary
The measurement of anti-Xa activity is classically used for the dose adjustement of unfractionated heparin (UFH) treatment and to monitor reversal of UFH by protamine during cardiac surgery with cardi...
Detailed Description
Any hospitalized patient receiving UFH in the intensive, cardiac surgery and medicine departments of the participating centres will be offered the study by investigator. It will be included in the stu...
Eligibility Criteria
Inclusion
- Patients over the age of 18;
- Hospitalized patients to receive UFH;
- No patient opposition.
- Patients will be divided into four groups:
- Group 1: patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine.
- Group 2: patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
- Group 3: hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
- Group 4: patients hospitalized in a medical non-intensive care ward..
Exclusion
- pregnant or lactating women;
- adults subject to legal protection (safeguarding of justice, guardianship, guardianship), persons deprived of their liberty.
Key Trial Info
Start Date :
January 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 16 2021
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT04700670
Start Date
January 16 2020
End Date
January 16 2021
Last Update
February 9 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bordeaux
Bordeaux, France, 33604
2
CHU de Dijon
Dijon, France, 21033
3
CH de Versailles
Le Chesnay, France, 78150
4
CHU de Lille
Lille, France, 59037